{"corpus_id":6793687,"paper_sha":"31282491037120a933df442078db18957b552786","doi":"10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","arxiv_id":null,"pmid":791473,"pmcid":null,"mag_id":2087824134,"dblp_id":null,"acl_id":null,"title":"Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma","year":1976,"publication_date":"1976-10-01","venue":"Cancer","journal":{"name":"Cancer","pages":null,"volume":"38"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, U.S. Gov't, P.H.S."],"s2_fields_of_study":["Medicine"],"reference_count":21,"citation_count":842,"influential_citation_count":21,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Cyclophosphamide","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D003520"},{"d":"Cytarabine","mj":false,"qs":[{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D003561"},{"d":"Doxorubicin","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D004317"},{"d":"Drug Therapy, Combination","mj":false,"ui":"D004359"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Lymphoma","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"pathology","mj":false,"ui":"Q000473"}],"ui":"D008223"},{"d":"Lymphoma, Large B-Cell, Diffuse","mj":false,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"}],"ui":"D016403"},{"d":"Lymphoma, Non-Hodgkin","mj":false,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"}],"ui":"D008228"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Prednisone","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D011241"},{"d":"Remission, Spontaneous","mj":false,"ui":"D012075"},{"d":"Time Factors","mj":false,"ui":"D013997"},{"d":"Vincristine","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D014750"}],"chemicals":[{"n":"Cytarabine","ui":"D003561","reg":"04079A1RDZ"},{"n":"Vincristine","ui":"D014750","reg":"5J49Q6B70F"},{"n":"Doxorubicin","ui":"D004317","reg":"80168379AG"},{"n":"Cyclophosphamide","ui":"D003520","reg":"8N3DW7272P"},{"n":"Prednisone","ui":"D011241","reg":"VB0R961HZT"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%28197610%2938%3A4%3C1484%3A%3AAID-CNCR2820380407%3E3.0.CO%3B2-I","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/31282491037120a933df442078db18957b552786","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Combination chemotherapy with CHOP (cyclophosphamide, Adriamycin, vincristine, and prednisone) and HOP (Adrimycin, vincristine, and prednisone, was used as treatment for patients with pathologically staged, advanced non-Hodgkin's lymphoma. Among 204 evaluable patients treated on CHOP there were 71% complete remissions with 92% overall responses. Among the 216 evaluable patients on HOP there were 61% complete remissions and 88% responses. Complete remission rates among patients with histiocytic lymphoma were comparable to those of patients with lymphocytic disease. Patients with nodular lymphoma had higher rates of complete remission than their counterparts with diffuse lymphoma. This was noted with both CHOP (78% vs. 67%) and HOP (67% vs. 60%) induction therapy. Rapid responses were common, as more than 14% of complete remissions and 66% of overall responses were achieved with the first course of treatment. Patients in complete remission have been maintained with either cyclophosphamide, vincristine, and prednisone (COP) or arabinosyl cytosine, vincristine, and prednisone (OAP). After 1 year, 86% of patients on COP and 80% on OAP are projected to be free of disease.","claims":[{"public_id":"cl_03591658db5e89280332789ee5e05f26","status":"active","text":"After 1 year, patients maintained with COP or OAP are projected to be free of disease at rates of 86% and 80%, respectively.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_03591658db5e89280332789ee5e05f26"},{"public_id":"cl_e0902b4de2a1d4978a762497d6e18021","status":"active","text":"CHOP produced 71% complete remissions and 92% overall responses in 204 evaluable patients with advanced non-Hodgkin's lymphoma.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_e0902b4de2a1d4978a762497d6e18021"},{"public_id":"cl_6f2b0dbb4387aa0259bfd4faf07d8c71","status":"active","text":"Complete remission rates for histiocytic lymphoma were comparable to those for lymphocytic disease.","confidence":0.9,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_6f2b0dbb4387aa0259bfd4faf07d8c71"},{"public_id":"cl_7534d473c26758faf3fc9f296bdc7dc5","status":"active","text":"HOP produced 61% complete remissions and 88% overall responses in 216 evaluable patients with advanced non-Hodgkin's lymphoma.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7534d473c26758faf3fc9f296bdc7dc5"},{"public_id":"cl_3e5f828c39eca417cb5020aed4f7208c","status":"active","text":"Nodular lymphoma had higher complete remission rates than diffuse lymphoma under both CHOP and HOP induction therapy.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_3e5f828c39eca417cb5020aed4f7208c"},{"public_id":"cl_38c176787f724903f9609e8d1358b718","status":"active","text":"Rapid responses were common, with more than 14% of complete remissions and 66% of overall responses achieved with the first course of treatment.","confidence":0.92,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_38c176787f724903f9609e8d1358b718"}],"concepts":[{"public_id":"co_1286c02c5043233107bafa3e974f68ee","status":"active","name":"OAP","description":"A maintenance chemotherapy regimen containing arabinosyl cytosine, vincristine, and prednisone.","types":["chemotherapy regimen"],"aliases":["arabinosyl cytosine, vincristine, and prednisone"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1286c02c5043233107bafa3e974f68ee"},{"public_id":"co_33db0d5b7afbdf542c9792fefc3c6bb3","status":"active","name":"CHOP","description":"A combination chemotherapy regimen containing cyclophosphamide, Adriamycin, vincristine, and prednisone.","types":["chemotherapy regimen"],"aliases":["cyclophosphamide, Adriamycin, vincristine, and prednisone"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_33db0d5b7afbdf542c9792fefc3c6bb3"},{"public_id":"co_387543277a219bdd33f3c584dcaaf019","status":"active","name":"COP","description":"A maintenance chemotherapy regimen containing cyclophosphamide, vincristine, and prednisone.","types":["chemotherapy regimen"],"aliases":["cyclophosphamide, vincristine, and prednisone"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_387543277a219bdd33f3c584dcaaf019"},{"public_id":"co_4d1534db24cf29531bccd1e18a969425","status":"active","name":"first course of treatment","description":"The initial chemotherapy cycle given at the start of induction therapy.","types":["treatment phase"],"aliases":["first course"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4d1534db24cf29531bccd1e18a969425"},{"public_id":"co_6080da420699c430035fc815b9018508","status":"active","name":"advanced non-Hodgkin's lymphoma","description":"A pathologically staged advanced form of non-Hodgkin's lymphoma treated with the reported regimens.","types":["disease"],"aliases":["advanced non-Hodgkin lymphoma"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6080da420699c430035fc815b9018508"},{"public_id":"co_789ce13b9daece3e018e420803a5fdd1","status":"active","name":"diffuse lymphoma","description":"A lymphoma pattern characterized by diffuse growth, used for comparison with nodular lymphoma.","types":["disease subtype"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_789ce13b9daece3e018e420803a5fdd1"},{"public_id":"co_91f28a81d5112592744026522d116636","status":"active","name":"free of disease","description":"A disease-free status projected at one year after maintenance therapy.","types":["outcome"],"aliases":["disease-free"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_91f28a81d5112592744026522d116636"},{"public_id":"co_920024d341e9de6606bc2e6ad6da3a94","status":"active","name":"complete remission","description":"A treatment outcome in which no detectable disease remains.","types":["outcome"],"aliases":["CR"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_920024d341e9de6606bc2e6ad6da3a94"},{"public_id":"co_aca5770bf3ab8401d1a803666aa73312","status":"active","name":"histiocytic lymphoma","description":"A lymphoma subtype compared with lymphocytic disease in remission outcomes.","types":["disease subtype"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_aca5770bf3ab8401d1a803666aa73312"},{"public_id":"co_c47f7bbb05afeeadd9ead4291556da02","status":"active","name":"HOP","description":"A combination chemotherapy regimen containing Adriamycin, vincristine, and prednisone.","types":["chemotherapy regimen"],"aliases":["Adriamycin, vincristine, and prednisone"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c47f7bbb05afeeadd9ead4291556da02"},{"public_id":"co_df7e208d6d67e32c9451491b4206ee93","status":"active","name":"lymphocytic disease","description":"A lymphoid disease subtype used for comparison of remission rates.","types":["disease subtype"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_df7e208d6d67e32c9451491b4206ee93"},{"public_id":"co_e6d4009750f9393acc34a103413dac54","status":"active","name":"nodular lymphoma","description":"A lymphoma pattern characterized by nodular growth, compared with diffuse lymphoma.","types":["disease subtype"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e6d4009750f9393acc34a103413dac54"},{"public_id":"co_fcf57680d602fa324483db529a2d1600","status":"active","name":"overall response","description":"The proportion of patients whose disease responded to treatment, including complete and partial responses.","types":["outcome"],"aliases":["response rate"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_fcf57680d602fa324483db529a2d1600"}],"external_ids":{"DOI":"10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","ArXiv":null,"PubMed":791473,"PubMedCentral":null,"MAG":2087824134,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%28197610%2938%3A4%3C1484%3A%3AAID-CNCR2820380407%3E3.0.CO%3B2-I","landing_url":"https://www.semanticscholar.org/paper/31282491037120a933df442078db18957b552786","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":633292,"paper_uid":"87579653-dcdc-477c-b4f8-bf17e68abed6","canonical_identity":{"paper_id":633292,"paper_uid":"87579653-dcdc-477c-b4f8-bf17e68abed6","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/6793687"}